Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy.

Autor: Moll-Udina, Aina, Miguel Escuder, Lucía, Hernanz, Inés, Llorenç, Victor, Fonollosa, Alex, Cordero Coma, Miguel, Sainz de la Maza, Maite, Espinosa, Gerard, González Guijarro, J. Jacobo, Lopez Lopez, Fernando, Alba-Linero, Carmen, Hernández, Marisa, Martínez Costa, Lucía, Celdrán Vivancos, Diego, Giralt, Lena, Artaraz, Joseba, Soler Bartrina, Pablo, Jódar Márquez, Margarita, García de Vicuña, Rosario, Esquinas, Cristina
Předmět:
Zdroj: Ocular Immunology & Inflammation; 2021, Vol. 29 Issue 7/8, p1591-1598, 8p
Abstrakt: Purpose: To assess the efficacy and safety of adalimumab in elderly patients with noninfectious uveitis (NIU).Methods: An observational, retrospective, multicenter study was done. Changes in best-corrected visual acuity (BCVA), inflammatory activity parameters, central retinal thickness (CRT), and the occurrence of adverse events (AE) developed during follow-up were recorded.Results: A total of 82 eyes from 41 patients 60 years of age and older with noninfectious uveitis treated with adalimumab were included. A significant improvement in BCVA (71.5 to 75.4 letters, p = .001) and in CRT (311.1 μm to 265 μm, p = .001) was observed. Moreover, a significant decrease from baseline in the rate of patients with anterior chamber cell (ACC) >0+ (34.6% to 5.7%, p = <0.001) or vitreous haze>0+ (21.3% to 4.3%, p = .002) was determined. AEs were observed in 11 patients (26.8%).Conclusion: Adalimumab can be safe and efficacious for the treatment of NIU in patients 60 years of age and older. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje